Incannex Healthcare (IXHL) Q1 2027 earnings summary

Executive summary

• IHL-42X advanced into patient dosing in the DREAMzz Phase 2 dose-optimization study in August 2026; completion is estimated for mid-2027.

• PSX-001 development planning continues after positive Phase 2 PsiGAD1 results, FDA IND clearance for PsiGAD2, and MHRA scientific advice.

Financial highlights

• No customer revenue in the quarter; material revenue is not expected until drug candidates receive approval.

• Operating expenses were $3.436m vs. $6.794m YoY; operating loss was $3.436m vs. $6.794m.

• Net loss improved to $1.938m from $6.407m; comprehensive loss was $1.548m vs. $6.184m.

• Cash and cash equivalents were $68.267m at September 30, 2026, vs. $67.711m at June 30, 2026.

• Operating cash flow was positive $521k vs. cash used of $9.163m YoY, reflecting working-capital movements and $3.4m of R&D tax receipts.

Outlook and guidance

• Existing unrestricted cash is expected to fund planned operating expenses and capital expenditures for at least 12 months from the financial statement issuance date.

• R&D expenses are expected to increase substantially as clinical and preclinical programs advance; future costs depend on trial scope, timing, enrollment and regulatory requirements.

• DREAMzz dose-selection data are intended to inform the planned Phase 3 design; study completion is estimated for mid-2027.

• Material revenue is not expected unless and until drug candidates are approved.